A Late Phase II Clinical Trial of KDT-3594 in Patients With Parkinson's Disease

Summary

This trial is a late phase II, multicenter, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy, safety, and pharmacokinetics of KDT-3594 administered at escalating doses ranging from 0.25 to 2 mg per day for 17 weeks in patients with advanced PD with levodopa.

Timeline

Start

2024-12-16

Primary completion

2026-04

Completion

2026-04

Drugs

Indications